| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; and 2 Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois
Activation of the PI3k/Akt pathway controls key cellular processes and contributes to tumorigenesis in vivo, but investigation of the PI3k/Akt pathway has been limited by the lack of specific inhibitors directed against Akt. To develop Akt inhibitors, we used molecular modeling of the pleckstrin homology (PH) domain of Akt to guide synthesis of structurally modified phosphatidylinositol ether lipid analogues (PIAs). Here, we characterize the biochemical and cellular effects of PIAs. Of 24 compounds tested, five PIAs with modifications at two sites on the inositol ring inhibited Akt with IC50s < 5 µM. Molecular modeling identified putative interactions of PIAs with the phosphoinositide-binding site in the PH domain of Akt, and growth factor-induced translocation of Akt to the plasma membrane was inhibited by PIA administration. Inhibition of Akt occurred rapidly and was maintained for hours. PIAs decreased phosphorylation of many downstream targets of Akt without affecting upstream kinases, such as PI3k or phosphoinositide-dependent kinase-1, or members of other kinase pathways such as extracellular signal-regulated kinase. Importantly, PIAs increased apoptosis 20–30-fold in cancer cell lines with high levels of endogenous Akt activity but only 4–5-fold in cancer cell lines with low levels of Akt activity. These studies identify PIAs as effective Akt inhibitors, and provide proof of principle for targeting the PH domain of Akt.
This article has been cited by other articles:
|
|
 |
|
  W. Han, J. J. Gills, R. M. Memmott, S. Lam, and P. A. Dennis The Chemopreventive Agent Myoinositol Inhibits Akt and Extracellular Signal-Regulated Kinase in Bronchial Lesions from Heavy Smokers Cancer Prevention Research, April 1, 2009; 2(4): 370 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Pluskota, N. M. Woody, D. Szpak, C. M. Ballantyne, D. A. Soloviev, D. I. Simon, and E. F. Plow Expression, activation, and function of integrin {alpha}M{beta}2 (Mac-1) on neutrophil-derived microparticles Blood, September 15, 2008; 112(6): 2327 - 2335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Memmott, J. J. Gills, M. Hollingshead, M. C. Powers, Z. Chen, B. Kemp, A. Kozikowski, and P. A. Dennis Phosphatidylinositol Ether Lipid Analogues Induce AMP-Activated Protein Kinase Dependent Death in LKB1-Mutant Non Small Cell Lung Cancer Cells Cancer Res., January 15, 2008; 68(2): 580 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rao, I. B. Lobov, J. E. Vallance, K. Tsujikawa, I. Shiojima, S. Akunuru, K. Walsh, L. E. Benjamin, and R. A. Lang Obligatory participation of macrophages in an angiopoietin 2-mediated cell death switch Development, December 15, 2007; 134(24): 4449 - 4458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Gills, S. S. Castillo, C. Zhang, P. A. Petukhov, R. M. Memmott, M. Hollingshead, N. Warfel, J. Han, A. P. Kozikowski, and P. A. Dennis Phosphatidylinositol Ether Lipid Analogues That Inhibit AKT Also Independently Activate the Stress Kinase, p38{alpha}, through MKK3/6-independent and -dependent Mechanisms J. Biol. Chem., September 14, 2007; 282(37): 27020 - 27029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Noguchi, V. Ropars, C. Roumestand, and F. Suizu Proto-oncogene TCL1: more than just a coactivator for Akt FASEB J, August 1, 2007; 21(10): 2273 - 2284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Song, H. S. Sekhon, A. Lu, J. Arredondo, D. Sauer, C. Gravett, G. P. Mark, S. A. Grando, and E. R. Spindel M3 Muscarinic Receptor Antagonists Inhibit Small Cell Lung Carcinoma Growth and Mitogen-Activated Protein Kinase Phosphorylation Induced by Acetylcholine Secretion Cancer Res., April 15, 2007; 67(8): 3936 - 3944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Romano, M. Pertuit, R. Rasolonjanahary, J.-V. Barnier, K. Magalon, A. Enjalbert, and C. Gerard Regulation of the RAP1/RAF-1/Extracellularly Regulated Kinase-1/2 Cascade and Prolactin Release by the Phosphoinositide 3-Kinase/AKT Pathway in Pituitary Cells Endocrinology, December 1, 2006; 147(12): 6036 - 6045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Roudier, O. Mistafa, and U. Stenius Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol. Cancer Ther., November 1, 2006; 5(11): 2706 - 2715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Rojo, J. Tabernero, J. Albanell, E. Van Cutsem, A. Ohtsu, T. Doi, W. Koizumi, K. Shirao, H. Takiuchi, S. R. Cajal, et al. Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma J. Clin. Oncol., September 10, 2006; 24(26): 4309 - 4316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Hartmann, B. Digon-Sontgerath, A. Koch, A. Waha, E. Endl, I. Dani, D. Denkhaus, C. G. Goodyer, N. Sorensen, O. D. Wiestler, et al. Phosphatidylinositol 3'-Kinase/AKT Signaling Is Activated in Medulloblastoma Cell Proliferation and Is Associated with Reduced Expression of PTEN. Clin. Cancer Res., May 15, 2006; 12(10): 3019 - 3027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Gills, S. Holbeck, M. Hollingshead, S. M. Hewitt, A. P. Kozikowski, and P. A. Dennis Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol. Cancer Ther., March 1, 2006; 5(3): 713 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mijatovic, A. Op De Beeck, E. Van Quaquebeke, J. Dewelle, F. Darro, Y. de Launoit, and R. Kiss The cardenolide UNBS1450 is able to deactivate nuclear factor {kappa}B-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol. Cancer Ther., February 1, 2006; 5(2): 391 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tsurutani, J. Fukuoka, H. Tsurutani, J. H. Shih, S. M. Hewitt, W. D. Travis, J. Jen, and P. A. Dennis Evaluation of Two Phosphorylation Sites Improves the Prognostic Significance of Akt Activation in Non-Small-Cell Lung Cancer Tumors J. Clin. Oncol., January 10, 2006; 24(2): 306 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Denlinger, B. K. Rundall, and D. R. Jones Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1422 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Dalwadi, K. Krysan, N. Heuze-Vourc'h, M. Dohadwala, D. Elashoff, S. Sharma, N. Cacalano, A. Lichtenstein, and S. Dubinett Cyclooxygenase-2-Dependent Activation of Signal Transducer and Activator of Transcription 3 by Interleukin-6 in Non-Small Cell Lung Cancer Clin. Cancer Res., November 1, 2005; 11(21): 7674 - 7682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hachem and R. B. Gartenhaus Oncogenes as molecular targets in lymphoma Blood, September 15, 2005; 106(6): 1911 - 1923. [Full Text] [PDF]
|
|
|
|
 |
|
 T Frogne, J S Jepsen, S S Larsen, C K Fog, B L Brockdorff, and A E Lykkesfeldt Antiestrogen-resistant human breast cancer cells require activated Protein Kinase B/Akt for growth Endocr. Relat. Cancer, September 1, 2005; 12(3): 599 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shah, W. A. Swain, D. Richardson, J. Edwards, D. J. Stewart, C. M. Richardson, D. E.B. Swinson, D. Patel, J. L. Jones, and K. J. O'Byrne Phospho-Akt Expression Is Associated with a Favorable Outcome in Non-Small Cell Lung Cancer Clin. Cancer Res., April 15, 2005; 11(8): 2930 - 2936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Li, J. Jaboin, P. A. Dennis, and C. J. Thiele Genetic and Pharmacologic Identification of Akt as a Mediator of Brain-Derived Neurotrophic Factor/TrkB Rescue of Neuroblastoma Cells from Chemotherapy-Induced Cell Death Cancer Res., March 15, 2005; 65(6): 2070 - 2075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Di-Poi, C. Y. Ng, N. S. Tan, Z. Yang, B. A. Hemmings, B. Desvergne, L. Michalik, and W. Wahli Epithelium-Mesenchyme Interactions Control the Activity of Peroxisome Proliferator-Activated Receptor {beta}/{delta} during Hair Follicle Development Mol. Cell. Biol., March 1, 2005; 25(5): 1696 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Caron, A. Yacoub, M. Li, X. Zhu, C. Mitchell, Y. Hong, W. Hawkins, T. Sasazuki, S. Shirasawa, A. P. Kozikowski, et al. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival Mol. Cancer Ther., February 1, 2005; 4(2): 257 - 270. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
